In a prospective, pilot study of 11 patients, one patient [age and sex not stated] was described, who developed neutropenia and thrombocytopenia following treatment with vinblastine for acute myeloid leukaemia (AML). The patient diagnosed with non-M3 AML. Subsequently, the patient received a single dose of IV vinblastine 6 mg/m 2 . However, the patient developed grade 4 neutropenia and thrombocytopenia secondary to vinblastine. The patient also developed SARS-COV-2 infection [duration of treatment to reaction onset and outcome not stated].